Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Purpose: Current clinical classification of pancreatic ductal adenocarcinoma (PDAC) is unable to predict prognosis or response to chemo- or immunotherapy and does not take into account the host reaction to PDAC cells. Our aim is to classify PDAC according to host- and tumor-related factors into clinically/biologically relevant subtypes by integrating molecular and microenvironmental findings. Experimental Design: A well-characterized PDAC cohort (n = 110) underwent next-generation sequencing with a hot spot cancer panel while next-generation tissue microarrays were immunostained for CD3, CD4, CD8, CD20, PD-L1, p63, hyaluronan-mediated motility receptor (RHAMM), and DNA mismatch repair proteins. Previous data on FOXP3 were integrated. Immune cell counts and protein expression were correlated with tumor-derived driver mutations, clinicopathologic features (TNM 8th edition, 2017), survival, and epithelial–mesenchymal transition (EMT)–like tumor budding. Results: Three PDAC subtypes were identified: the “immune escape” (54%), poor in T and B cells and enriched in FOXP3+ regulatory T cells (Treg), with high-grade budding, frequent CDKN2A, SMAD4, and PIK3CA mutations, and poor outcome; the "immune rich" (35%), rich in T and B cells and poorer in FOXP3+ Tregs, with infrequent budding, lower CDKN2A and PIK3CA mutation rate, and better outcome and a subpopulation with tertiary lymphoid tissue (TLT), mutations in DNA damage response genes (STK11 and ATM), and the best outcome; and the "immune exhausted" (11%), with immunogenic microenvironment and two subpopulations—one with PD-L1 expression and a high PIK3CA mutation rate and a microsatellite-unstable subpopulation with a high prevalence of JAK3 mutations. The combination of low budding, low stromal FOXP3 counts, presence of TLTs, and absence of CDKN2A mutations confers significant survival advantage in patients with PDAC. Conclusions: Immune host responses correlate with tumor characteristics, leading to morphologically recognizable PDAC subtypes with prognostic/predictive significance. Clin Cancer Res; 24(18); 4444–54. ©2018 AACR. See related commentary by Khalil and O'Reilly, p. 4355
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“Finally, all candidate mutations were manually reviewed using the Integrative Genomics Viewer8 (29).”
MethodGenomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 3×
“The expression pattern as well as the molecular and clinical characteristics of the immune-escape phenotype largely overlapwith the squamous subtypedescribedbyBailey and colleagues (16) or the quasi-mesenchymal subtype described by Collisson and colleagues (17), whereas the pattern that characterizes the immune-rich p…”
BackgroundMethodIntegrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · cited 1×
“More recently, an integrated genomic analysis of PDACs identified four molecular subtypes named squamous, pancreatic progenitor, immunogenic and aberrantly differentiated endocrine exocrine indicating differences in the molecular evolution of PDAC subtypes and identifying opportunities for therapeutic development (16-…”
BackgroundRegulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · cited 2×
“Furthermore, it suggests that tumor budding cells, which are significantly more frequent in the immune-escape subtype, are embedded in and probably interact with the tumor-permissive microenvironment, while their close interaction with the FOXP3-Tregs opens possibilities for therapeutic intervention (31).”
BackgroundREporting recommendations for tumour MARKer prognostic studies (REMARK).
for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626 · cited 1×
“Mutations in STK11 have been found to promote activation of the PI3K/AKT/mTOR pathway pointing to new drug targets (46).”
BackgroundO'Brien, D. P., Sandanayake, N. S., Jenkinson, C., Gentry-Maharaj, A., Apostolidou, S., Fourkala, E.-O., Camuzeaux, S., Blyuss, O., Gunu, R., Dawnay, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0365 · Cited by 200 · cited 1×
“Our findings are in accordance with previous studies, where an association between high CA-19-9 values and worse prognosis has been demonstrated (59).”
ResultThe TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance
Ahmed, S., Bradshaw, A.-D., Gera, S., Dewan, M., & Xu, R. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6010005 · Cited by 174 · cited 1×
“SMAD4 acts as central mediator of TGF-β signaling and its inactivation is frequently found in PDACs (3, 41).”
Background
Cited by
Tumour budding in solid cancers
Lugli, A., Zlobec, I., Berger, M. D., Kirsch, R., & Nagtegaal, I. D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0422-y · Cited by 366
Self-citationKaramitopoulou, E. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0479-5 · Cited by 301
Self-citationLuchini, C., Brosens, L. A. A., Wood, L. D., Chatterjee, D., Shin, J. I., Sciammarella, C., Fiadone, G., Malleo, G., Salvia, R., Kryklyva, V., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320726 · Cited by 258
Suppression of p16 alleviates the senescence-associated secretory phenotype
(2021) · doi:10.18632/aging.202640 · Cited by 84
McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells · doi:10.3390/cells11142155 · Cited by 49
“This also increased the levels of forkhead box P3 positive (Fox3P) Tregs and was associated with a lower level of survival in PDAC patients [16].”
Background
Metadata
- Authors
- Wartenberg, M., Cibin, S., Zlobec, I., Vassella, E., Eppenberger-Castori, S., Terracciano, L., Eichmann, M. D., Worni, M., Gloor, B., Perren, A., & Karamitopoulou, E.
- Venue
- Clinical Cancer Research
- Published
- 2018-09-14
- Volume
- 24
- Issue
- 18
- Pages
- 4444-4454
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2802851196
- Cited by
- 197
- References
- 8
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-3401
- The paper
- Wartenberg, M., Cibin, S., Zlobec, I., Vassella, E., Eppenberger-Castori, S., Terracciano, L., Eichmann, M. D., Worni, M., Gloor, B., Perren, A., & Karamitopoulou, E. (2018). Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-3401
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.